These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 32557243)

  • 21. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands.
    van der Hooft CS; Sturkenboom MC; van Grootheest K; Kingma HJ; Stricker BH
    Drug Saf; 2006; 29(2):161-8. PubMed ID: 16454543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
    Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
    Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Knowledge creation about adverse drug reactions in the paediatric population].
    Aagaard L
    Ugeskr Laeger; 2013 Feb; 175(6):342-5. PubMed ID: 23402239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilance.
    Alloush R; van Lint J; van Marum RJ; Hermens WWAJJ; Jessurun NT
    Expert Opin Drug Saf; 2024 Jul; 23(7):925-935. PubMed ID: 37961907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
    Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
    Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.
    Neubert A; Dormann H; Weiss J; Egger T; Criegee-Rieck M; Rascher W; Brune K; Hinz B
    Drug Saf; 2004; 27(13):1059-67. PubMed ID: 15471510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
    Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
    Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants].
    Patrignani A; Palmieri G; Ciampani N; Moretti V; Mariani A; Racca L
    G Ital Cardiol (Rome); 2018 Jan; 19(1):54-61. PubMed ID: 29451510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.
    Nicol C; Moulis F; Bondon-Guitton E; Durrieu G; Montastruc JL; Bagheri H
    Therapie; 2019 Oct; 74(5):521-525. PubMed ID: 31029402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agreement between a regional pharmacovigilance centre and an adjudication committee regarding adverse drug reactions on a cohort of hospitalised children.
    Pages N; Bounabi A; Boussaha I; Ndiaye M; Portefaix A; Simeon G; Guy C; Stagnara J; Paret N; Vial T; Eftekhari P; Floret D; Gajdos V; Langhendries JP; Bleyzac N; Alberti C; Jacqz-Aigrain E; Nguyen KA; Kassai B;
    Therapie; 2022; 77(4):397-404. PubMed ID: 34998623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical students as junior adverse drug event managers facilitating reporting of ADRs.
    Reumerman MO; Tichelaar J; Richir MC; van Agtmael MA
    Br J Clin Pharmacol; 2021 Dec; 87(12):4853-4860. PubMed ID: 33955031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015.
    van Hunsel F; de Waal S; Härmark L
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):977-983. PubMed ID: 28524293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
    Geer MI; Koul PA; Tanki SA; Shah MY
    J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Knowledge, attitudes and practice regarding pharmacovigilance and adverse drug reaction reporting among physicians and pharmacists in Egypt: a step toward personalized medicine implementation.
    Aziz AA; Rogers S; Hassanien O; Shalaby L; Nagy M
    Per Med; 2022 Nov; 19(6):495-507. PubMed ID: 36239598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.